Garraway WM, Collins GN, Lee RJ (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet 338:469–471
Article
PubMed
CAS
Google Scholar
Rosen R, Altwein J, Boyle P, et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44:637–649
Article
PubMed
Google Scholar
Giuliano F, Chevret-Masson M, Tsatsaris A, et al (2002) Prevalence of erectile dysfunction in France: results of an epidemiological survey of a representative sample of 1004 men. Eur Urol 42:382–389
Article
PubMed
Google Scholar
McVary KT (2005) Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 47:838–845
Article
PubMed
Google Scholar
Braun MH, Sommer F, Haupt G, et al (2003) Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical “Aging Male” symptoms? Results of the “Cologne Male Survey”
Ponholzer A, Temml C, Obermayr R, Madersbacher S (2004) Association between lower urinary tract symptoms and erectile dysfunction. Urology 64:772–776
Article
PubMed
Google Scholar
Shiri R, Häkkinen J, Koskimäki J, et al (2005) Association between the bothersomeness of lower urinary tract symptoms and the prevalence of erectile dysfunction. J Sex Med 2:438–444
Article
PubMed
Google Scholar
Elhilali M, Emberton M, Matzkin H, et al (2006) Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in real-life practice. BJU Int 97:513–519
Article
PubMed
CAS
Google Scholar
Köhler TS, McVary KT (2009) The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 55:38–48
Article
PubMed
Google Scholar
Abrams P, Cardozo L, Fall M, et al (2002) The standardisation of terminology of lower urinary tract function. Report from the standardisation subcommittee of the ICS. Neurourol Urodyn 21:167–178
Article
PubMed
Google Scholar
Haab F, Amarenco G, Coloby P, et al (2004) Terminologie des troubles fonctionnels du bas appareil urinaire: adaptation française de la terminologie de l’International Continence Society. Prog Urol 14:1103–1111
PubMed
Google Scholar
Desgranchamps F, De La Taille A, Azzouzi AR, et al (2006) Management of non complicated BPH: proposition for a renewed decision tree. World J Urol 24:367–370
Article
Google Scholar
Irani J, Brown CT, Van Der Meulen J, Emberton MA (2003) Review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? BJU Int 92:937–942
Article
PubMed
CAS
Google Scholar
Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cordoso JV, et al (2005) The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in decade. BJU Int 7:1045–1048
Article
Google Scholar
Beckman TJ, Mynderse LA (2005) Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Poc 10:1356–1362
Article
Google Scholar
Murray E, Davis H, Tai SS, et al (2001) Randomised controlled trial of an interactive multimedia decision aid on benign prostatic hyperplasia in primary care. BMJ 323:1–6
Article
Google Scholar
Abrams P, Kaplan S, De Koning, et al (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175:999–1004
Article
PubMed
CAS
Google Scholar
McConnell JD, Roehrborn CG, Bautista OM, et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398
Article
PubMed
CAS
Google Scholar
Kirby RS, Roehrborn CG, Boyle P, et al (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61:1119–1126
Article
Google Scholar
Nichol MB, Knight TK, Wu J, et al (2009) Evaluation use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 5:2214–2221
Article
Google Scholar
Stene E (1994) Three years safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43:284–294
Article
Google Scholar
Van Kerrebroeck P, Jardin A, Laval KU, Van Cangh P (2000) Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily vs 2,5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI study group. Eur Urol 3:306–313
Article
Google Scholar
Lepor H (1998) Long term of tamsulosine in benign prostatic hyperplasia: placebo-controlled, double-bind extension of phase III trial. Urology 6:901–906
Article
Google Scholar
Phillips B. Levels of evidence and grades of recommandation. Oxford centre for evidence-based medicine.http://www.cebm.net/levels_of_evidence.asp
Roehrborn CG, McVary KT, Elion-Mboussa A, Vikturp L (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180:1228–1234
Article
PubMed
CAS
Google Scholar
McVary K, Monnig W, Camps Jr, et al (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177:1071–1077
Article
PubMed
CAS
Google Scholar
Stief C, Porst H, Neuser D, et al (2008) A randomised, placebo controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53:1236–1244
Article
PubMed
CAS
Google Scholar
Dmochowski R, Roehrborn C, Klise S, et al (2010) Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. Urology 183:1092–1097
Article
CAS
Google Scholar
Tamimi N, Mincik I, Haughie S, et al (2010) A placebocontrolled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int 106:674–680
Article
PubMed
CAS
Google Scholar
Giuliano FA, Lamb J, Crossland A, et al (2010) A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesteras type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJU Int 106:666–673
Article
PubMed
CAS
Google Scholar
Roherborn CG, Kaminetsky JC, Auerbach SM, et al (2010) Changes in peak urinary flow an voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 105:502–507
Article
Google Scholar
Ergedie RB, Auerbach S, Roehrborn CG, et al (2012) Tadalafil 2,5 mg or 5 mg administred once daily for 12 weeks in men both erectile dysfunction and signs and symptoms of nenign prostatic hyperplasia: results of a randomized, placebo-controlled, doubleblind study. J Sex Med 9:271–281
Article
Google Scholar
Porst H, Kim ED, Casabé AR, et al (2011) Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 60:1105–1113
Article
PubMed
CAS
Google Scholar
Oelke M, Giuliano F, Mirone V, et al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomized, parallel, placebo-controlled clinical trial. Eur Urol 61:917–925
Article
PubMed
CAS
Google Scholar
Broderick GA, Brock GB, Roehrborn CG, et al (2010) Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 75:1452–1458
Article
PubMed
Google Scholar
McVary KT, Roehrborn CG, Kaminetsky JC, et al (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177:1401–1407
Article
PubMed
CAS
Google Scholar
Bechara A, Romano S, Casabé A, et al (2008) Comparative efficacy assessment of tamsulosine vs tamsulosine plus tadlafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5:2170–2178
Article
PubMed
CAS
Google Scholar
Kaplan SA, Gonzales RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723
Article
PubMed
CAS
Google Scholar
Mulhall JP, Guhring P, Parker M, Hopps C (2006) Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3:662–667
Article
PubMed
CAS
Google Scholar
Sairam K, Kulinskaya E, McNicholas TA, et al (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90:836–839
Article
PubMed
CAS
Google Scholar
Nieminen T, Tammela LJ, Koobi T, Kahonen M (2006) The effects of tamsulosine and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. J Urol 176:2551–2556
Article
PubMed
CAS
Google Scholar
van Leeuwen JH, Castro R, Busse M, Bemelmans BL (2006) The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 50:440–453
Article
PubMed
Google Scholar
Ückert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166:2484–2490
Article
PubMed
Google Scholar
Waldkirch E, Ückert S, Langnäse K (2007) Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 52:495–502
Article
PubMed
CAS
Google Scholar
Ückert S, Oelke M, Stief CG, et al (2006) Immunohistochemical distribution of cAMP and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49:740–745
Article
PubMed
Google Scholar
Takeda M, Tang R, Shapiro E, et al (1995) Effects of nitric oxide on human and canine prostates. Urology 45:440–446
Article
PubMed
CAS
Google Scholar
Guh JH, Chueh SC, Hwang TL, et al (1998) Cell proliferation in human prostatic smooth muscle cells involves the modulation of protein kinase C isozymes. Eur J Pharmacol 359:281–284
Article
PubMed
CAS
Google Scholar
Cook AL, Haynes JM (2004) Protein kinase G II mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 16:253–261
Article
PubMed
CAS
Google Scholar
Bloch W, Klotz T, Loch C, et al (1997) Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 33:1–8
Article
PubMed
CAS
Google Scholar
Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51:1202–1216
Article
PubMed
CAS
Google Scholar
Werkstrom V, Svensson A, Andersson KE, Hedlund P (2006) Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int 98:414–423
Article
PubMed
Google Scholar
Bittencourt JA, Tano T, Gajar SA, et al (2009) Relaxant effects of sildenafil on the human isolated bladder neck. Urology 73:427–430
Article
PubMed
Google Scholar
Filippi S, Morelli A, Sandner P, et al (2007) Characterization and functional role androgen-dependent PDE5 activity in the bladder. Endocrinology 148:1019–1029
Article
PubMed
CAS
Google Scholar
Fathian-Sabet B, Bloch W, Klotz T, et al (2001) Localization of constitutive nitric oxide synthase isoforms and the nitric oxide target enzyme soluble guanylyl cyclase in the human bladder. J Urol 5:1724–1729
Article
Google Scholar
Truss MC, Uckert S, Stief CG, et al (1996) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. Urol Res 24:123–128
PubMed
CAS
Google Scholar
Birder LA, Apodaca G, De Groat WC, Kanai AJ (1998) Adrenergic and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 12:226–229
Google Scholar
Oger S, Behr-Roussel D, Gorny D, et al (2008) Signaling pathways involved in sildenafil-induced relaxation of human detrusor. 102th meeting American Urological Association. Orlando, USA
Persson K, Igawa Y, Mattinsson A, Andersson KE (1992) Effects of inhibition of the L-arginine/ nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol 107:178–184
Article
PubMed
CAS
PubMed Central
Google Scholar
Moon A (2002) Influence of nitric oxide signalling pathways on pre-contracted human detrusor smooth muscle in vitro. BJU Int 89:942–949
Article
PubMed
CAS
Google Scholar
Yanai Y, Hashitani H, Sasaki S, et al (2008) Role of nitric oxide/ cyclic GMP pathway in regulating spontaneous excitations in detrusor smooth muscle of the guinea-pig bladder. Neurourol Urodyn 27:446–453
Article
PubMed
CAS
Google Scholar
Morelli A, Filippi S, Fibbi B, et al (2009) Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho-kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 6:1594–1608
Article
PubMed
CAS
Google Scholar
Werkstrom V, Hedlund P, Lee T, Andersson KE (2009) Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder. BJU Int 104:1740–1745
Article
PubMed
Google Scholar
Matsumoto S, Hanai T, Uemura H (2010) Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats. Int Urol Nephrol 42:53–56
Article
PubMed
CAS
Google Scholar
Smet PJ, Jonavicius J, Marshall VR, de Vente J (1996) Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience 71:337–348
Article
PubMed
CAS
Google Scholar
Ozawa H, Chancellor MB, Jung SY, et al (1996) Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. J Urol 6:2211–2216
Google Scholar
Tinel H, Stelte-Ludwig B, Hutter J, Sandner P (2006) Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98:1259–1263
Article
PubMed
CAS
Google Scholar
Behr-Roussel D, Oger S, Caisey S, et al (2011). Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol 59:272–279
Article
PubMed
CAS
Google Scholar
Caremel R, Oger-Roussel S, Behr-Roussel D, et al (2010) Nitirc oxyde/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturation reflex in the rat. Eur Urol 58:616–625
Article
PubMed
CAS
Google Scholar
Berger AP, Deibl M, Leonhartsberger N, et al (2005) Vascular damage as a risk factor for benign prostatic hyperplasia and érectile dysfonction. BJU Int 96:1073–1088
Article
PubMed
Google Scholar
Pinggera A, Schuster F, Frauscher G, Bartsch H (2004) Sildenafil citrate causes a three fold increase in periurethral prostatic blood flow. J Urol 171:A1348
Article
Google Scholar
Morelli A, Filippi S, Comeglio P, et al (2010) Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 7:107–120
Article
PubMed
CAS
Google Scholar